* Prestige Consumer Healthcare Inc PBH.N PBH is expected
to show a fall in quarterly revenue when it reports results on
February 2.
* The Tarrytown New York-based company is expected to
report a
0.3% decrease in revenue to $273.725 million from $274.47
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. The company's guidance on
November 3 2022, for the period ended December 31, was for
revenue between $271.00 million and $274.00 million.
* Refinitiv's mean analyst estimate for Prestige Consumer
Healthcare Inc is for earnings of $1.01 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Prestige
Consumer
Healthcare Inc is $71, above its last closing price of $65.49.
The company's guidance on November 3 2022 for the period ended
December 31 was for gross profit margin of USD55%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 1.00 1.00 1.02 Beat 1.8
Jun. 30 2022 1.04 1.04 1.09 Beat 5
Mar. 31 2022 0.89 0.89 0.91 Beat 2.6
Dec. 31 2021 0.88 0.88 0.99 Beat 12.1
Sep. 0.99 0.99 1.02 Beat 3.4
30 2021
Jun. 30 2021 0.87 0.87 1.14 Beat 31.5
Mar. 31 2021 0.79 0.78 0.79 Beat 1.3
Dec. 31 2020 0.77 0.77 0.81 Beat 5.6
This summary was machine generated January 31 at 18:57 GMT. All
figures in US dollars unless otherwise stated